Conference Preview: American College of Rheumatology Convergence 2025 | HCPLive
The American College of Rheumatology (ACR) Convergence 2025 takes place in Chicago, Illinois, from Friday, October 24 through Wednesday, …
Google News
RheumNow
12 yr study of 115 Systemic Sclerosis pts shows Finger-to-palm distance (tip 4th finger to distal palmar crease) may be
12 yr study of 115 Systemic Sclerosis pts shows Finger-to-palm distance (tip 4th finger to distal palmar crease) may be
British Society of Rheumatology
Injury and local injection and the risk of foot/ankle osteoarthritis: a case–control study in retired UK male professional footballers
Abstract Objective The objective of this study was to examine whether foot/ankle injury and injection contribute to the risk of
RheumNow
UK National Joint Registry study of 1.5 million TKR and THA (2010 to 2022); trends show median Length of hosp stay (LOS
UK National Joint Registry study of 1.5 million TKR and THA (2010 to 2022); trends show median Length of hosp
Google News
New Rheumatology specialist joins Meritus in Hagerstown and Frederick – LocalNews1.org
Meritus Health proudly welcomes board-certified rheumatologist Mary R. Romanic, M.D., specializing in arthritis and joint diseases.
Google News
AbbVie bolsters immunology hold as Rinvoq again edges out Humira – FirstWord Pharma
SELECT-COMPARE trial, published in Arthritis & Rheumatology in 2019, also pitted Rinvoq against Humira in RA patients, specifically those who
RheumNow
Phase 3b/4 head-to-head SELECT-SWITCH study tested Humira vs Rinvoq in 492 RA MTX pts failing a TNFi then Rx w/ ADA vs U
Phase 3b/4 head-to-head SELECT-SWITCH study tested Humira vs Rinvoq in 492 RA MTX pts failing a TNFi then Rx w/
The Rheumatologist
The Rheum Advocate: A Fresh Look for the Same Trusted Voice
Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy
The Rheumatologist
ACR Delegation to Address AI, Non-Compete Agreements at Interim AMA House of Delegates Meeting
The ACR’s resolutions at the Interim HOD meeting, held Nov. 14–18, will address non-compete agreements as well as the use
RheumNow
Study from Czech ATTRA registry of 8,543 RA pts 641 (7.5%) met criteria for D2T-RA & 1,825 achieved remission (21%).
Study from Czech ATTRA registry of 8,543 RA pts 641 (7.5%) met criteria for D2T-RA & 1,825 achieved remission (21%).
RheumNow
Colchicine Ineffective in Long COVID
Colchicine Ineffective in Long COVID jjcush@gmail.com Tue, 10/21/2025 – 14:20
ClinicalTrials.gov
Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)
Conditions: Interstitial Lung Disease Due to Systemic Disease (Disorder); Interstitial Lung Disease in Patients With Rheumatoid Arthritis; Interstitial Lung Disease
ClinicalTrials.gov
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus; Idiopahic Inflammatory Myopathies; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Sjögren’s Syndrome; Antiphospholipid Syndrome; Immune Thrombocytopenia; Systemic Sclerosis Interventions:
ClinicalTrials.gov
Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)
Conditions: Interstitial Lung Disease Due to Systemic Disease (Disorder); Interstitial Lung Disease in Patients With Rheumatoid Arthritis; Interstitial Lung Disease
ClinicalTrials.gov
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Conditions: Arthritis, Rheumatoid Interventions: Drug: Tulisokibart; Drug: Placebo; Drug: Methotrexate Sponsors: Merck Sharp & Dohme LLC Recruiting
ClinicalTrials.gov
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus; Idiopahic Inflammatory Myopathies; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Sjögren’s Syndrome; Antiphospholipid Syndrome; Immune Thrombocytopenia; Systemic Sclerosis Interventions:
ClinicalTrials.gov
A Study of SPY072 in Rheumatic Disease
Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Joint Disease; PsA (Psoriatic Arthritis); AxSpA; Rheumatologic Disease Interventions: Drug:
ClinicalTrials.gov
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Conditions: Arthritis, Rheumatoid Interventions: Drug: Tulisokibart; Drug: Placebo; Drug: Methotrexate Sponsors: Merck Sharp & Dohme LLC Recruiting
ClinicalTrials.gov
A Study of SPY072 in Rheumatic Disease
Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Joint Disease; PsA (Psoriatic Arthritis); AxSpA; Rheumatologic Disease Interventions: Drug:
ClinicalTrials.gov
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Conditions: Rheumatoid Arthritis Interventions: Drug: Afimkibart; Drug: Placebo Sponsors: Hoffmann-La Roche Not yet recruiting
ClinicalTrials.gov
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Conditions: Refractory Autoimmune Diseases Interventions: Genetic: BMS-986515; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Tocilizumab Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb
ClinicalTrials.gov
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Conditions: Refractory Rheumatoid Arthritis (RA); Idiopathic Inflammatory Myopathies (IIMs); Systemic Sclerosis (SSc); Rheumatoid Arthritis (RA; IIM; Myositis; Scleroderma; Sjogren Syndrome;
ClinicalTrials.gov
Study of GS-0151 in Participants With Rheumatoid Arthritis
Conditions: Rheumatoid Arthritis Interventions: Drug: GS-0151; Drug: Placebo Sponsors: Gilead Sciences Recruiting
ClinicalTrials.gov
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Conditions: Rheumatoid Arthritis Interventions: Drug: LY3541860 Sponsors: Eli Lilly and Company Recruiting
ClinicalTrials.gov
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Conditions: Rheumatoid Arthritis Interventions: Drug: IMVT-1402; Drug: Placebo Sponsors: Immunovant Sciences GmbH Recruiting
Google News
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American … – Taiwan News
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence. GlobeNewswire Oct. 21, 2025
RheumNow
30% of RA pts have non-alcoholic fatty liver disease (NAFLD). In 170 pts on MTX or biologics (TNFi, IL-6i)- NAFLD was fo
30% of RA pts have non-alcoholic fatty liver disease (NAFLD). In 170 pts on MTX or biologics (TNFi, IL-6i)- NAFLD